Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
AssigneesVaccinex, Inc., The Sydney Children's Hospital Network
InventorsYilin Mao, Wendy Gold, Elizabeth E. Evans, Maurice Zauderer
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for alleviating symptoms in a subject having Rett syndrome, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D).
Claims16
A method of alleviating symptoms in a subject having Rett syndrome, comprising administering to the subject an effective amount of an isolated antibody or antigen-binding fragment thereof which specifically binds to semaphorin-4D (SEMA4D), wherein the antibody or fragment thereof comprises (1) a variable heavy chain (VH) comprising VH CDRs 1-3 comprising SEQ ID NOs:
- 3, 4, and 5, respectively, and a variable light chain (VL) comprising VL CDRs 1-3 comprising SEQ ID NOS:
- 8, 9, and 10, respectively;
- or (2) a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs:
- 22, 23, and 24, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs:
- 26, 27, and 28, respectively.
Dependencies are inferred from the claim text.